Postmarketing surveillance for drug safety in pregnancy: The organization of Teratology Information Services project

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 70, Issue 12, 2004, Pages 944-947

  Felix, Robert J ^a   Jones, Kenneth Lyons ^a   Johnson, Kathleen A ^a   McCloskey, Carolyn A ^b   Chambers, Christina D ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug safety; Pregnancy exposures; Teratogens

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; CLONAZEPAM; CODEINE; DERMATOLOGICAL AGENT; FLUOXETINE; FLUTICASONE; GABAPENTIN; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; IMMUNOLOGIC AGENT; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; NATURAL PRODUCT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PREDNISONE; RESPIRATORY TRACT AGENT; RETINOIC ACID; SALBUTAMOL; SALICYLIC ACID; SERTRALINE; UNINDEXED DRUG; URINARY TRACT AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CANADA; DRUG ABUSE; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FETAL ALCOHOL SYNDROME; GESTATIONAL AGE; HUMAN; INFORMATION SERVICE; MAJOR CLINICAL STUDY; POSTMARKETING SURVEILLANCE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; TERATOLOGY; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ADULT; DATA COLLECTION; DRUG THERAPY; FEMALE; HOTLINES; HUMANS; INFORMATION SERVICES; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY; TERATOGENS;

OTIS;

EID: 11144350610     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20090     Document Type: Article

References (15)

1. Addis A, Moretti ME, Ahmed Syed F, et al. 2001. Fetal effects of cocaine: an updated meta-analysis. Reprod Toxicol 15:341-369.
2. Bonati M, Bortolus R, Marchetti F, et al. 1990. Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol 38:325-328.
3. Brent RL. 1986. The effects of embryonic and fetal exposure to x-ray, microwaves, and ultrasound. Clin Perinatol 13:615-648.
4. Chambers CD, Johnson KA, Dick LM, et al. 1996. Birth outcome in women taking fluoxetine. N Engl J Med 335:1010-1015.
5. Drug Facts and Comparisons. 2002. St. Louis, MO: Facts and Comparisons, Wolters Kluwer.
6. Einarson A, Phillips E, Mawji F, et al. 1998. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523-525.
7. Forrest JD. Epidemiology of unintended pregnancy and contraceptive use. 1994. Am J Obstet Gynecol 170:1485-1489.
8. Jones KL, Smith DW. 1973. Recognition of the Fetal Alcohol Syndrome in early infancy. Lancet 2:999-1001.
9. Jones KL, Johnson KA, Dick LM, et al. 2002. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Teratology 65:125-130.
10. Kaufman DW, Kelly JP, Rosenberg L, et al. 2002. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA 287:337-344.
11. Lacroix I, Damase-Michele C, Lapeyre-Mestre M, Montastruc JL. 2000. Prescription of drugs during pregnancy in France. Lancet 356:1735-1736.
12. Leen-Mitchell M, Martinez L, Gallegos S, et al. 2000. History of organized teratology information services in North America. Teratology 61:314-317.
13. Shuhaiber S, Pastuszak A, Schick B, et al. 1998. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 51:581-583.
14. U.S. Food and Drug Administration. 2003. Code of Federal Regulations, Title 21, Volume 4. Washington, DC: U.S. Government Printing Office. pp. 21-32.
15. Webster WS, Freeman JA. 2001. Is this drug safe in pregnancy? Reprod Toxicol 2001;15:619-629.